Hangzhou AllTest Biotech CO.,LTD 

      Your Reliable Rapid Test Partner!

About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home News

Quest for the Optimal Cardiovascular Risk Biomarker

I'm Online Chat Now
China Hangzhou AllTest Biotech CO.,LTD certification
China Hangzhou AllTest Biotech CO.,LTD certification
I like the products and service provided by AllTest. They really take our interest into consideration.

—— Mr John Smith England

My oldest daughter actually has Lyme disease. She spent almost 1 year in a wheelchair because of Lyme. She is doing very well now. I used 2 of the samples. 1 to test my Lyme diagnosed daughter and 1 to test my daughter who does not have Lyme. Your tests worked well. My daughter with Lyme tested positive and the one who does not tested negative.

—— Ms Sheila

Whenever I have the requests,AllTest always give me the satisfied reply at the first time.

—— Mrs Julie Tschetter Belgium

As the old customer of AllTest since 2009, we should thank the great work have been done by AllTest to support us gain more market share and profit

—— Mr Robin Seifert Germany

Company News
Quest for the Optimal Cardiovascular Risk Biomarker

Glucagon-like peptide 1 outperforms established cardiac markers as an early risk predictor for acute myocardial infarction.
A study in the European Heart Journal suggests that glucagon-like peptide 1 levels (GLP-1) could help stratify risk of acute myocardial infarction (MI), guiding more personalized treatment and better clinical outcomes. Squaring off against more established cardiac markers such as troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP), GLP-1 emerged as a top performer in predicting early cardiovascular events in hospitalized MI patients.
Experimental studies have shown associations between elevated GLP-1 levels and acute MI. In patients with diabetes, GLP-1 receptor agonists have been known to improve cardiac outcomes. Building on these results, researchers enrolled 918 patients with either ST-segment elevation MI or non-ST-segment elevation MI (NSTEMI). They assessed total GLP-1, NT-proBNP levels, and Global Registry of Acute Coronary Events (GRACE) scores for each patient upon admission to the hospital.
The study had three primary outcomes: first occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke. Using Kaplan-Meier survival plots and univariable Cox regression analyses, the researchers found a definitive association between GLP-1 and adverse cardiac events. In other analysis, they also determined that GLP-1 was a strong marker for early cardiac events. Perhaps most significantly, GLP-1 bested four other markers —troponin T measured via high-sensitivity assay, glomerular filtration rate using the CKD-EPI equation, C-reactive protein measured with a high-sensitivity assay (hs-CRP), and NT-proBNP—in prognosticating events 30 days after hospital admission. “Moreover, admission GLP-1 levels added additional value to the GRACE risk score in NSTEMI patients,” the investigators noted.
GLP-1’s hazard ratio for adverse outcomes remained significant even after adjusting for a number of variables such as age, sex, family history of cardiovascular disease, smoking, diabetes, hypertension, hypercholesterinaemia, and other biomarkers. Future studies should focus on larger cohorts that include repeated GLP-1 measurements to better assess its value as a marker for MI patients, the researchers suggested.
The biomarker’s eventual impact on treatment regimens and outcomes for MI patients remains unknown at this point, wrote Leonardo Roever, MHS, MD, Gary Tse, PhD, Francesco Versaci, MD, and Giuseppe Biondi-Zoccai, MD, in a related editorial. Nevertheless, they expressed optimism that GLP-1 would establish itself as a routine part of clinical care, despite some challenges.
“I believe that with more studies, GLP-1 can be used with confidence to stratify the risk of MI,” Roever told.
Other experts also were encouraged by the results. The study makes an interesting connection between the gut pathology and acute coronary syndromes, Alan Wu, PhD, director of clinical chemistry and toxicology at the University of California, San Francisco told. “We are learning more and more of the importance of gastrointestinal issues with various diseases. The fact that GLP-1 appears to be protective,” is a finding that might have therapeutic implications. The measure to adjust hazard ratios to traditional risk factors and biomarkers makes these observations even more interesting, added Wu.

Pub Time : 2020-03-23 11:27:54 >> News list
Contact Details
Hangzhou AllTest Biotech CO.,LTD

Contact Person: Mrs. Selina

Tel: +86 13989889852

Fax: 86-571-56267856

Send your inquiry directly to us